Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-07-04
2006-07-04
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07071230
ABSTRACT:
Methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to exposure to noise. Combinations of these time periods can also be employed.
REFERENCES:
patent: 2732400 (1956-01-01), Weiss
patent: 4426372 (1984-01-01), Borch
patent: 4961926 (1990-10-01), Gabrilove
patent: 5002755 (1991-03-01), Mitchell et al.
patent: 5292773 (1994-03-01), Hirsch et al.
patent: 5430064 (1995-07-01), Hirsch et al.
patent: 5466678 (1995-11-01), Kawabata et al.
patent: 5667791 (1997-09-01), Hersh et al.
patent: 6177434 (2001-01-01), Kopke et al.
patent: 6265386 (2001-07-01), Campbell
patent: 6649621 (2003-11-01), Kopke et al.
patent: 06 200 04 (1994-10-01), None
patent: WO 98/14182 (1998-04-01), None
patent: WO 03/045334 (2003-06-01), None
Campbell et al., Hearing Research, (1996) vol. 102, No. 1-2, pp. 90-98, Abstractb Only.
W. Wesley Alden, et al., “Exacerbation of Cisplatin-Induced Nephrotoxicity by Methionine,”Chem.-Biol. Interactions, 1984, 48, pp. 121-124.
Mark A. Basinger, et al., “Dithiocarbamate-Induced Biliary Platinum Excretion and the Control of cis-Platinum Nephrotoxicity,”TOxicology and Applied Pharmacology, 1989, 97, pp. 279-288.
Mark A. Basinger, et al., “L-Methionine Antagonism of cis-Platinum Nephrotoxicity,”Toxicology and Applied Pharmacology, 1990, 108, pp. 1-15.
Mark A. Basinger, et al., “L-Methionine Suppresses Pathological Sequelae of cis-Platinum in the Rat.”Fundamental and Applied Toxicology, 1990, 14, pp. 568-577.
Pieter J. Boogaard, et al., 4-Methylthiobenzoic Acide Reduces Cisplatin Nephrotoxicity In Rats Without Compromising Anti-Tumor Activity,Biochemical Pharmacology, 1991, vol. 41, No. 12, pp. 1997-2003.
Pieter J. Boogaard, et al., “The Role of Methallothionein in the Reduction of Cisplatin-Induced Nephrotoxicity by Bi3+-Pretreatment in the RatIn VivoandIn Vitro, Are Antioxidant Properties of Methallothionein More Relevant than Platinum Binding?”,Biochemical Pharmacology, 1991, vol. 41, No. 3, pp. 369-375.
Joseph H. Burchenal, et al., “Studies of Cross-Resistance, Synergistric Combinations and Blocking of Activity of Platinum Derivates,”Biochimie, 1978, 60, No. 9, pp. 961-965.
Kathleen C.M. Campbell, et al., “D-Methionine Provides Excellent Protection from Cisplatin Ototoxicity in the Rat,”Hearing Research, 1996, 102, pp. 90-98.
Kathleen C.M. Campbell, et al., “D-Methionine Provides Protection Against Cisplatin Damage the Rat Stria Vascularis: A Semi-Quantitative Analysis,”Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology, Feb. 15-19, 1998, Abstract No. 537, pp. 135.
Michael W. Church, et al., “The Comparative Effects of SOdium Thiosulfate, Diethyldithiocarbamate, Fosfomycin and WR-2721 on Ameliorating Cisplatin-Induced Ototoxicity,”Hearing Research, 1995, Jan. 2, 1986, pp. 195-203.
Patricia M. Deegan et al., “The nephrotoxicity, cytotoxicity and renal handling of cisplatin-methionine complex in male Wistar rats,”Toxicology, 1994, 89, pp. 1-14.
Peter C. Dedon, et al., “Chracterization of the Reactions of Platinum Antitumor Agents with Biologic and Nonbiologic Sulfur-Containing Nucleophiles,”Biochemical Pharmacology, 1987, vol. 36, No. 12, pp. 1955-1964.
Mendel Friedman, et al., “The Utilization and Safety of Isomeric Sulfur-Containing Amino Acids in Mice,”J. Nutr., 1984, 114, pp. 2301-2310.
Ramin Gabaizadeh, et al., “Protection of Both Auditory Hair Cells and Auditory Neurons from Cisplatin Induced Damage,”Acta Otolaryngol(Stockholm), 1997, 117, pp. 232-238.
David R. Gandara, et al., “Evaluation of Cisplatin Dose Intensity: Current Status and Future Prospects,”Anticancer Research, 1989, 9, pp. 1121-1128.
David R. Gandara, et al., “Cisplatin Chemoprotection and Rescue: Pharmacologic Modulation of Toxicity,”Seminars in Oncology, Feb. 1991, vol. 18, No. 1, SUppl. 3, pp. 49-55.
Donna Glover, et al., “Clinical Trials of WR-2721 and Cis-Platinum,”I. J. Radiation Oncology. Biology. Physics, May 1989, vol. 16, No. 5, pp. 1201-1204.
Jorg Hannermann, et al., “Cisplatin-Induced Lipid Peroxidation and Decrease of Gluconeogenesis in Rat Kidney Cortex: Different Effects of Antioxidants and Radical Scavengers,”Toxicology, 1988, 51, pp. 119-132.
Mark M. Jones, et al., “Inhibition of cis-diamminedichloroplatinum (II)-induced renal toxicity in the rat,”Cancer Chemotherapy and Pharmacology, 1986, 17, pp. 38-42.
Mark M. Jones, et al., “Control of Nephrotoxicity in the Rat during Repeated cis-Platinum Treatments,”Journal of Applied Toxicology, 1989, vol. 9(4), pp. 229-233.
Mark M. Jones, et al., “Thiol and Thioether Suppression of Cis-Platinum-Induced Nephrotoxicity in Rats Bearing the Walker 256 Carcinosarcoma,”Anticancer Research, 1989, 9: 1937-1942.
Mark M. Jones, et al., “Thioether Suppression of Cisplatin Nephrotoxicity in the Rat,”Anticancer Research, 1991, 11 pp. 449-454.
Mark M. Jones, et al., “Coadministration of Dimethyl Sulfoxide Reduces Cisplatin Nephrotoxicity,”Anticancer Research, 1991, 11, pp. 1939-1942.
Mark M. Jones, et al., “Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity,”Toxicology, 19191, 68: pp. 227-247.
Mark M. Jones, et al., “Control of the Nephrotoxicity of Cisplatin by Clinically Used Sulfur-Containing Compounds,”Fundamental and Applied Toxicology, 1992, 18, pp. 181-188.
Constance Kies, et al., “Comparative Value of L-, DL-, and D-Methionine Supplementation of an Oat-based Diet for Humans,”J. Nutr., 1975, 105, pp. 809-814.
Richard D. Kopke, et al., “Use of Organotypic Cultures of Corti's Organ to Study the Protective Effects of Antioxidant Molecules on Cisplatin-Induced Damage of Auditory Hair Cells,”The American Journal of Otology, 1997, 18, 559-571.
K. D. Korver, et al., “Round window application of D-methionine provides cisplatin otoprotection,”Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology, Feb. 15-19, 1998, Abstract No. 536, p. 135.
Jan Egil Melvik, et al., “Reduction of cis-cisDichlorodiammineplatinum-Induced Cell Inactivation by Methionine,”Inorganica Chimica Acta, 1987, 137, pp. 115-118.
Thomas J. Montine et al., “Role of Endogenous Sulfur-Containing Nucleophiles in an In Vitro Model of cis-Diamminedichloroplatinum(II)-Induced Nephrotoxicity,”Biochemical Pharmacology, 1990, vol. 39, No. 11, pp. 1751-1757.
Sachiko Nakano, et al., “Protentiation of Cisplatin-Induced Lipid Peroxidation in Kidney Cortical Slices by Glutathione Depletion,”Japan. J. Pharmacol., (1989), 50, pp. 87-92.
T. Ormond, et al., “Reduced NephrotoxicityIn VivoandIn Vitroof Cisplatin-Methionine Complex,”Brit. J. Pharmacol. (suppl)., (1988), 95, p. 584P.
Kenneth J. Printen, et al., “Utilization of D-methionine during total parenteral nutrition in postsurgical patients,”The American Journal of Clinical Nutrition, Jun. 1979 , 32, pp. 1200-1205.
Radhika P. Ravi, et al., “Relationship of Pharmacodynamic Effects of Cisplatin to the Glutathione Levels in Cochlea, Inferior Colliculus and Kidney,”Pharmacologist, 1991, 33(3), D-19, 402, p. 217.
Radhika Ravi, et al., “Diethyldithiocarbamate Protects Against Cisplatin Ototoxicity and Nephrotoxicity,”Otolaryngology Head and Neck Surgery, 1992, 107(2), Poster 5, p. 232.
D. H. Reser, et al., “Physiological evidence for protection from cis-platin ototoxicity by D- and L-methionine in vivo,”Abstracts of the Twenty-First Annual Mid-Winter Research Mee
Board of Trustees of Southern Illinois University
Cook Rebecca
Senniger Powers
LandOfFree
Therapeutic use of D-methionine to reduce the toxicity of noise does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of D-methionine to reduce the toxicity of noise, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of D-methionine to reduce the toxicity of noise will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561421